These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 476270)

  • 61. Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy.
    Lui VK; Karpuchas J; Dent PB; McCulloch PB; Blajchman MA
    Br J Cancer; 1975 Sep; 32(3):323-30. PubMed ID: 1233077
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Erythema multiforme as a complication of BCG scarification technique.
    Tschen EH; Jessen RT; Robertson G; Becker LE
    Arch Dermatol; 1979 May; 115(5):614-5. PubMed ID: 443840
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Successful transurethral intralesional BCG therapy of a bladder melanoma.
    deKernion JB; Golub SH; Gupta RK; Silverstein M; Morton DL
    Cancer; 1975 Nov; 36(5):1662-7. PubMed ID: 1192356
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
    Hedley DW; McElwain TJ; Currie GA
    Eur J Cancer (1965); 1977 Oct; 13(10):1169-73. PubMed ID: 923614
    [No Abstract]   [Full Text] [Related]  

  • 65. Serum associated leucocyte locomotion inhibition and leucocyte motility in malignant melanoma: effect of BCG treatment.
    Zielinski C; Pehamberger H; Endler AT; Knapp W
    Clin Exp Immunol; 1979 Oct; 38(1):92-8. PubMed ID: 393441
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Morton DL; Eilber FR; Holmes EC; Ramming KP
    Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
    Mastrangelo MJ; Bellet RE; Berkelhammer J; Clark WH
    Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adjuvant BCG immunotherapy for malignant melanoma.
    Paterson AH; Willans DJ; Jerry LM; Hanson J; McPherson TA
    Can Med Assoc J; 1984 Oct; 131(7):744-8. PubMed ID: 6383591
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of bacillus Calmette-Guerin immunotherapy on tumor antigen-induced lymphocyte-stimulated protein synthesis in melanoma patients.
    Roth JA; Golub SH; Holmes EC; Morton DL
    Surgery; 1975 Jul; 78(1):66-75. PubMed ID: 1138401
    [TBL] [Abstract][Full Text] [Related]  

  • 70. BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma.
    Morton DL; Eilber FR; Holmes EC; Sparks FC; Ramming K
    Med Clin North Am; 1976 May; 60(3):431-9. PubMed ID: 1271888
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intravenous administration of BCG in advanced melanoma patients.
    Orefice S; Cascinelli N; Vaglini M; Veronesi U
    Tumori; 1978; 64(4):437-43. PubMed ID: 684866
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin.
    Spitler LE; Levin AS; Wybran J
    Cell Immunol; 1976 Jan; 21(1):1-19. PubMed ID: 764975
    [No Abstract]   [Full Text] [Related]  

  • 74. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
    Nathanson L; Schoenfeld D; Regelson W; Colsky J; Mittelman A
    Cancer; 1979 May; 43(5):1630-5. PubMed ID: 376098
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Combined BCG and irradiation treatment of skin metastases originating from malignant melanoma.
    Plesnicar S; Rudolf Z
    Cancer; 1982 Sep; 50(6):1100-6. PubMed ID: 7104950
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Non-specific and specific immunotherapy in patients with melanoma.
    Seigler HF; Shingleton WW; Metzgar RS; Buckley CE; Bergoc PM; Miller DS; Fetter BF; Phaup MB
    Surgery; 1972 Jul; 72(1):162-74. PubMed ID: 4555924
    [No Abstract]   [Full Text] [Related]  

  • 77. Inconsistent response of B16 melanoma to BCG immunotherapy.
    Kreider JW; Bartlett GL; Purnell DM
    J Natl Cancer Inst; 1976 Apr; 56(4):803-10. PubMed ID: 1255799
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Adjuvant immunotherapy of malignant melanoma.
    Aranha GV; McKhann CF; Grage TB; Gunnarsson A; Simmons RL
    Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
    Green MD; MacKay IR; Buckley JC; Coates AS
    Aust N Z J Surg; 1979 Jun; 49(3):335-9. PubMed ID: 289374
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
    Tan JK; Ho VC
    J Dermatol Surg Oncol; 1993 Nov; 19(11):985-90. PubMed ID: 8245304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.